Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas

Roy, 2009, Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer, J Clin Oncol, 27, 5287, 10.1200/JCO.2009.23.5556

Whittaker, 1999, Design and therapeutic application of matrix metalloproteinase inhibitors, Chem Rev, 99, 2735, 10.1021/cr9804543

Bloomston, 2002, Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials, Ann Surg Oncol, 9, 668, 10.1007/BF02574483

Egeblad, 2002, New functions for the matrix metalloproteinases in cancer progression, Nat Rev Cancer, 2, 161, 10.1038/nrc745

Bhowmick, 2004, Stromal fibroblasts in cancer initiation and progression, Nature, 432, 332, 10.1038/nature03096

Kalluri, 2006, Fibroblasts in cancer, Nat Rev Cancer, 6, 392, 10.1038/nrc1877

Vihinen, 2002, Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets, Int J Cancer, 99, 157, 10.1002/ijc.10329

Itoh, 1998, Reduced angiogenesis and tumor progression in gelatinase A-deficient mice, Cancer Res, 58, 1048

Tallant, 2010, Matrix metalloproteinases: fold and function of their catalytic domains, Biochim Biophys Acta, 1803, 20, 10.1016/j.bbamcr.2009.04.003

Cerdà-Costa, 2014, Architecture and function of metallopeptidase catalytic domains, Protein Sci, 23, 123, 10.1002/pro.2400

Sternlicht, 1999, The Stromal proteinase MMP3/Stromelysin-1 promotes mammary carcinogenesis, Cell, 98, 137, 10.1016/S0092-8674(00)81009-0

Liu, 2006, Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer, Clin Chim Acta, 371, 92, 10.1016/j.cca.2006.02.026

Ueda, 2003, Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors, Oncogene, 22, 8716, 10.1038/sj.onc.1206962

Lakka, 2002, Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion, Oncogene, 21, 8011, 10.1038/sj.onc.1205894

Mehner, 2014, Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer, Oncotarget, 5, 2736, 10.18632/oncotarget.1932

Hofmann, 2000, Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression, J Pathology, 191, 245, 10.1002/1096-9896(2000)9999:9999<::AID-PATH632>3.0.CO;2-#

Stetler-Stevenson, 1999, Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention, J Clin Investigation, 103, 1237, 10.1172/JCI6870

Wilson, 1999, Regulation of intestinal α-defensin activation by the metalloproteinase matrilysin in innate host defense, Science, 286, 113, 10.1126/science.286.5437.113

Ii, 2006, Role of matrix metalloproteinase-7 (Matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis, Exp Biol Med, 231, 20, 10.1177/153537020623100103

Nagase, 2006, Structure and function of matrix metalloproteinases and TIMPs, Cardiovasc Res, 69, 562, 10.1016/j.cardiores.2005.12.002

Lemaître, 2006, Matrix metalloproteinases in development and disease, Birth Defects Res C Embryo Today, 78, 1, 10.1002/bdrc.20065

Alexander, 1996, Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation, Development, 122, 1723, 10.1242/dev.122.6.1723

Rodríguez, 2010, Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics, Biochimica Biophysica Acta, 1803, 39, 10.1016/j.bbamcr.2009.09.015

Massova, 1998, Matrix metalloproteinases: structures, evolution, and diversification, FASEB J, 12, 1075, 10.1096/fasebj.12.12.1075

Overall, 2002, Strategies for MMP inhibition in cancer: innovations for the post-trial era, Nat Rev Cancer, 2, 657, 10.1038/nrc884

Murphy, 1994, Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant, J Biol Chem, 269, 6632, 10.1016/S0021-9258(17)37419-7

Ohnishi, 2001, Cloning and characterization of a rat ortholog of MMP-23 (matrix metalloproteinase-23), a unique type of membrane-anchored matrix metalloproteinase and conditioned switching of its expression during the ovarian follicular development, Mol Endocrinol, 15, 747, 10.1210/mend.15.5.0638

Yang, 1997, A novel matrix metalloproteinase gene (XMMP) encoding vitronectin-like motifs is transiently expressed in Xenopus laevis early embryo development, J Biological Chem, 272, 13527, 10.1074/jbc.272.21.13527

Zucker, 2003, Membrane type-matrix metalloproteinases (MT-MMP), Curr Top Dev Biol, 54, 1, 10.1016/S0070-2153(03)54004-2

Jozic, 2005, X-ray structure of human proMMP-1: new insights into procollagenase activation and collagen binding, J Biological Chem, 280, 9578, 10.1074/jbc.M411084200

Maskos, 2005, Crystal structures of MMPs in complex with physiological and pharmacological inhibitors, Biochimie, 87, 249, 10.1016/j.biochi.2004.11.019

Park, 1991, Mutational analysis of the transin (rat stromelysin) autoinhibitor region demonstrates a role for residues surrounding the “cysteine switch”, J Biol Chem, 266, 1584, 10.1016/S0021-9258(18)52334-6

Vartak, 2007, Matrix metalloproteases: underutilized targets for drug delivery, J Drug Target, 15, 1, 10.1080/10611860600968967

Van Wart, 1990, The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family, Proc Natl Acad Sci USA, 87, 5578, 10.1073/pnas.87.14.5578

Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Dormán, 2010, Matrix metalloprotease inhibitors: a critical appraisal of design principles and proposed therapeutic utility, Drugs, 70, 949, 10.2165/11318390-000000000-00000

Hidalgo, 2001, Development of matrix metalloproteinase inhibitors in cancer therapy, J Natl Cancer Inst, 93, 178, 10.1093/jnci/93.3.178

Hu, 2007, Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases, Nat Rev Drug Discov, 6, 480, 10.1038/nrd2308

Rao, 2005, Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies, Curr Pharm Des, 11, 295, 10.2174/1381612053382115

Gialeli, 2011, Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting, FEBS J, 278, 16, 10.1111/j.1742-4658.2010.07919.x

Rasmussen, 1997, Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat, Pharmacol Ther, 75, 69, 10.1016/S0163-7258(97)00023-5

Steward, 1999, Marimastat (BB2516): current status of development, Cancer Chemother Pharmacol, 43, S56, 10.1007/s002800051099

Coussens, 2002, Matrix metalloproteinase inhibitors and cancer—trials and tribulations, Science, 295, 2387, 10.1126/science.1067100

Overall, 2006, Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy, Nat Rev Cancer, 6, 227, 10.1038/nrc1821

Agrawal, 2008, Zinc-binding groups modulate selective inhibition of MMPs, ChemMedChem, 3, 812, 10.1002/cmdc.200700290

Supuran, 2003, Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents, Med Res Rev, 23, 535, 10.1002/med.10047

Wood, 1998, CGS 27023A, a potent and orally active matrix metalloprotease inhibitor with antitumor activity, Proc Am Assoc Cancer Res

Fisher, 2006, Recent advances in MMP inhibitor design, Cancer Metastasis Rev, 25, 115, 10.1007/s10555-006-7894-9

2000

Hirte, 2006, Gynecol Oncol, 102, 300, 10.1016/j.ygyno.2005.12.020

Pavlaki, 2003, Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials, Cancer Metastasis Rev, 22, 177, 10.1023/A:1023047431869

Zucker, 2000, Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment, Oncogene, 19, 6642, 10.1038/sj.onc.1204097

McCawley, 2000, Matrix metalloproteinases: multifunctional contributors to tumor progression, Mol Med Today, 6, 149, 10.1016/S1357-4310(00)01686-5

Bergers, 1999, Effects of angiogenesis inhibitors on multistage carcinogenesis in mice, Science, 284, 808, 10.1126/science.284.5415.808

Devy, 2009, Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis, Cancer Res, 69, 1517, 10.1158/0008-5472.CAN-08-3255

Zhou, 1997, Cloning and expression in Escherichia coli of a human gelatinase B-inhibitory single-chain immunoglobulin variable fragment (scFv), FEBS Lett, 414, 562, 10.1016/S0014-5793(97)01072-7

Martens, 2007, A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains, Biochimica Biophysica Acta, 1770, 178, 10.1016/j.bbagen.2006.10.012

Klein, 2004, The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia, Crit Rev Oncol Hematol, 50, 87, 10.1016/j.critrevonc.2003.09.001

Westermarck, 1999, Regulation of matrix metalloproteinase expression in tumor invasion, FASEB J, 13, 781, 10.1096/fasebj.13.8.781

Xavier Gomis-Rüth, 2004, Hemopexin domains, Encycl Inorg Bioinorganic Chem, 10.1002/9781119951438.eibc0523

Cha, 2002, Structural basis of the adaptive molecular recognition by MMP9, J Mol Biol, 320, 1065, 10.1016/S0022-2836(02)00558-2

Zarrabi, 2011, Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration, J Biological Chem, 286, 33167, 10.1074/jbc.M111.256644

Remacle, 2012, Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth, Cancer Res, 72, 2339, 10.1158/0008-5472.CAN-11-4149

Dufour, 2011, Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9, Cancer Res, 71, 4977, 10.1158/0008-5472.CAN-10-4552

Dufour, 2010, Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides, J Biological Chem, 285, 35944, 10.1074/jbc.M109.091769

Mori, 2002, CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain, EMBO J, 21, 3949, 10.1093/emboj/cdf411

Lichte, 1996, The recombinant catalytic domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) induces activation of progelatinase A and progelatinase A complexed with TIMP-2, FEBS Lett, 397, 277, 10.1016/S0014-5793(96)01206-9

Dufour, 2008, Role of the hemopexin domain of matrix metalloproteinases in cell migration, J Cell Physiol, 217, 643, 10.1002/jcp.21535

Higashi, 2013, Molecular design of a highly selective and strong protein inhibitor against matrix metalloproteinase-2 (MMP-2), J Biological Chem, 288, 9066, 10.1074/jbc.M112.441758

Golub, 1991, Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs, Crit Rev Oral Biol Med, 2, 297, 10.1177/10454411910020030201

Griffin, 2010, Tetracyclines: a pleitropic family of compounds with promising therapeutic properties, Rev Literature, 299, C539

Smith, 1999, Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme, Arthritis Rheum, 42, 1140, 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7

García, 2005, Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass Spectrometry, Mol Pharmacol, 67, 1128, 10.1124/mol.104.006346

Perdigão, 2013, Dentin adhesion and MMPs: a comprehensive review, J Esthet Restor Dent, 25, 219, 10.1111/jerd.12016

Jones, 2005, Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic, Drugs Today, 41, 637, 10.1358/dot.2005.41.10.937460

Zhu, 2012, Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting, ACS Nano, 6, 3491, 10.1021/nn300524f

Zhang, 2013, Multifunctional Envelope-type mesoporous silica nanoparticles for tumor-triggered targeting drug delivery, J Am Chem Soc, 135, 5068, 10.1021/ja312004m

Wang, 2011, Natriuretic peptide receptor a as a novel target for prostate cancer, Mol Cancer, 10, 56, 10.1186/1476-4598-10-56

Subramanian, 2014, Atrial natriuretic peptide (ANP) inhibits DMBA/croton oil induced skin tumor growth by modulating NF-κB, MMPs, and infiltrating mast cells in Swiss albino mice, Eur J Pharmacol, 740, 388, 10.1016/j.ejphar.2014.07.024

Warner, 2008, MDI 301, a nonirritating retinoid, improves abrasion wound healing in damaged/atrophic skin, Wound Repair Regen, 16, 117, 10.1111/j.1524-475X.2007.00338.x

Varani, 2002, All-trans retinoic acid improves structure and function of diabetic rat skin in organ culture, Diabetes, 51, 3510, 10.2337/diabetes.51.12.3510

Zeng, 2011, Effects of a synthetic retinoid on skin structure, matrix metalloproteinases, and procollagen in healthy and high-risk subjects with diabetes, J Diabetes Complications, 25, 398, 10.1016/j.jdiacomp.2011.10.002